Toll Free: 1-888-928-9744

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipeline Review, H1 2016

Published: Jun 22, 2016 | Pages: 45 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipeline Review, H1 2016', provides in depth analysis on Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted pipeline therapeutics. 

The report provides comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
- The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Therapeutics Development 6 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Products under Development by Stage of Development 6 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Products under Development by Therapy Area 7 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Products under Development by Indication 8 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Products under Development by Companies 12 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Products under Development by Universities/Institutes 15 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Companies Involved in Therapeutics Development 24 AskAt Inc. 24 Eisai Co., Ltd. 25 Eli Lilly and Company 26 Kaken Pharmaceutical Co., Ltd. 27 Ono Pharmaceutical Co., Ltd. 28 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drug Profiles 29 AAT-008 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 CR-6086 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 E-7046 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 ER-886046 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 grapiprant - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 KAG-308 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 ONO-4232 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 P-001 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Small Molecule to Antagonize EP4 Receptor for Inflammatory Pain - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Dormant Projects 40 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Discontinued Products 42 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Featured News & Press Releases 43 Jul 25, 2012: RaQualia Pharma Receives Allowance For EP4 Antagonist Substance Patent In Japan 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables
Number of Products under Development for, H1 2016 6 Number of Products under Development by Therapy Area, H1 2016 7 Number of Products under Development by Indication, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Products under Development by Companies, H1 2016 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Stage and Mechanism of Action, H1 2016 19 Number of Products by Stage and Route of Administration, H1 2016 21 Number of Products by Stage and Molecule Type, H1 2016 23 Pipeline by AskAt Inc., H1 2016 24 Pipeline by Eisai Co., Ltd., H1 2016 25 Pipeline by Eli Lilly and Company, H1 2016 26 Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2016 27 Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 28 Dormant Projects, H1 2016 40 Dormant Projects (Contd..1), H1 2016 41 Discontinued Products, H1 2016 42


List of Figures
Number of Products under Development for, H1 2016 6 Number of Products under Development by Therapy Area, H1 2016 7 Number of Products under Development by Top 10 Indication, H1 2016 8 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy/Combination Products, H1 2016 17 Number of Products by Mechanism of Actions, H1 2016 18 Number of Products by Stage and Mechanism of Actions, H1 2016 18 Number of Products by Routes of Administration, H1 2016 20 Number of Products by Stage and Routes of Administration, H1 2016 20 Number of Products by Molecule Types, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 22

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving cream

Read More...

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...

Global agricultural films market size is anticipated to reach USD 10.5 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to raise agricultural productivity, in order to meet surplus demand by growing population i

Read More...

Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance driv

Read More...

Global Bio polyethylene terephthalate (PET) market size is likely to be valued at USD 12.6 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing preference of biopolymers in numerous applications coupled with favorable gover

Read More...
Choose License Type
Single User - US $3500
Multi User - US $7000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify